Fusion Pharmaceuticals Inc. (FUSN)
Market Cap | 1.81B |
Revenue (ttm) | 2.07M |
Net Income (ttm) | -94.90M |
Shares Out | 84.69M |
EPS (ttm) | -1.45 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 1,564,243 |
Open | 21.30 |
Previous Close | 21.30 |
Day's Range | 21.25 - 21.37 |
52-Week Range | 2.31 - 21.44 |
Beta | -0.85 |
Analysts | Hold |
Price Target | 20.86 (-2.16%) |
Earnings Date | Mar 20, 2024 |
About FUSN
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor. It also conducting additional preclinical studies of FPI-1434 in combination with approved check... [Read more]
Financial Performance
In 2023, FUSN's revenue was $2.07 million, an increase of 41.55% compared to the previous year's $1.46 million. Losses were -$94.90 million, 8.32% more than in 2022.
Financial StatementsAnalyst Forecast
According to 11 analysts, the average rating for FUSN stock is "Hold." The 12-month stock price forecast is $20.86, which is a decrease of -2.16% from the latest price.
News
INVESTIGATION: The M&A Class Action Firm Announces an Investigation of Fusion Pharmaceuticals Inc. - FUSN
NEW YORK , March 26, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securit...
Fusion Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Clinical Program Updates
Company recently announced definitive agreement to be acquired by AstraZeneca FPI-2265 Phase 2/3 registrational program for patients with metastatic castration-resistant prostate cancer (mCRPC) expect...
FUSION PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Fusion Pharmaceuticals Inc. - FUSN
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Fusion Pharmaceu...
FUSN Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Fusion Pharmaceuticals Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Fusion Pharmaceuticals Inc. (NASDAQ: FUSN) to AstraZeneca is fair to Fusion shareholders....
AstraZeneca to buy Fusion Pharmaceuticals for up to $2.4 billion
AstraZeneca is buying Fusion Pharmaceuticals for $2.4 billion as the London-listed group looks to build its presence in cutting-edge cancer treatments.
AstraZeneca to buy Fusion Pharma for $2 billion in cash
AstraZeneca said on Tuesday it will buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash to boost its oncology portfolio.
Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer
Transaction includes actinium-based clinical-stage radioconjugate targeting PSMA for prostate cancer, pipeline of radioconjugates and state-of-the-art R&D and manufacturing facilities Fusion sharehold...
Fusion Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HAMILTON, ON and BOSTON, March 6, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as preci...
Fusion Pharmaceuticals to Present Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the 2024 AACR Annual Meeting
HAMILTON, ON and BOSTON , March 5, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec...
Fusion Pharmaceuticals to Present at Upcoming March Investor Conferences
HAMILTON, ON and BOSTON , Feb. 26, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec...
Fusion Pharmaceuticals Enters into Exclusive Worldwide License Agreement with Heidelberg University and Euratom for Actinium-Based PSMA Targeted Radiotherapy
FPI-2265 positioned to be the first approved PSMA targeted alpha therapy HAMILTON, ON and BOSTON, Feb. 16, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology co...
Fusion Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
HAMILTON, ON and BOSTON , Feb. 7, 2024 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as preci...
Fusion Pharmaceuticals Announces Clinical Program and Manufacturing Updates
Aligned with the FDA on submitted protocol for 225Ac-PSMA (FPI-2265) Phase 2/3 registrational program for patients with metastatic castration-resistant prostate cancer (mCRPC) Achieved target enrollme...
Fusion Pharma climbs as analyst flags radiopharmaceutical company as potential merger target
Fusion Pharmaceuticals Inc.'s stock FUSN, +16.69% was up by 5.3% in premarket trading on Wednesday, as analysts at Oppenheimer highlighted the company as a potential merger target. Fusion Pharmaceutic...
10 ‘better values' in the stock market, selected for the next two years
Since market valuations are always changing, along with outlooks for corporate revenue and earnings, any list of favored stocks is only a snapshot. Repeating the same analysis in the near term might l...
BWXT Medical Expands Collaboration with Fusion Pharmaceuticals Through Strengthened Actinium Supply and Access to Generator Technology
OTTAWA, Ontario--(BUSINESS WIRE)--BWXT Medical Expands Collaboration with Fusion Pharmaceuticals Through Strengthened Actinium Supply and Access to Generator Technology.
Fusion Pharmaceuticals Strengthens Actinium Supply with Onsite Isotope Production through Expanded BWXT Medical Collaboration
Collaboration enables Fusion to produce high purity actinium-225 at Company's GMP manufacturing facility Agreement furthers BWXT Medical's position as a global leader in medical isotope supply HAMILTO...
Fusion Pharmaceuticals to Present at Upcoming Investor Conferences
HAMILTON, ON and BOSTON , Nov. 8, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as preci...
Fusion Pharmaceuticals Announces Third Quarter 2023 Financial Results and Clinical Program Updates
Preliminary data for FPI-2265 (225Ac-PSMA I&T) in approximately 20 to 30 patients on track for Q1 2024 Data from Cohort 2 of the FPI-1434 Phase 1 study anticipated around year-end 2023 FPI-2068, a bis...
Fusion Pharmaceuticals Appoints Life Science Industry Leaders Jeremy Bender, Teresa Bitetti and David Meek to its Board of Directors
HAMILTON, ON and BOSTON , Oct. 16, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec...
Fusion Pharmaceuticals Announces Presentation of Preclinical Data Supporting FPI-2068, a Novel Targeted Alpha Therapy for EGFR-cMET Expressing Cancers
Data presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics FPI-2068 demonstrates anti-tumor activity in colorectal and lung tumor xenograft mouse m...
Fusion Pharmaceuticals to Present at Upcoming September Investor Conferences
HAMILTON, ON and BOSTON , Sept. 5, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec...
Fusion Pharmaceuticals Announces Second Quarter 2023 Financial Results and Clinical Program Updates
FPI-2265 (Ac-PSMA I&T) IND transferred to Fusion; program is enrolling patients and on track for Q1 2024 update Preliminary clinical data presented at the Society of Nuclear Medicine and Molecular Ima...
Fusion Pharmaceuticals to Present Interim Data from Phase 1 Trial of FPI-1434 in Patients with Solid Tumors Expressing IGF-1R
Preliminary Clinical Data with Cold/Hot Dosing Regimen Demonstrate Potential to Improve Therapeutic Index and Safety Profile Company Prioritizing Cold/Hot Dosing Regimen in Phase 1 Trial; Cohort 2 in ...
Fusion Pharmaceuticals to Present at the TD Cowen Radiopharmaceutical Innovation Summit
HAMILTON, ON and BOSTON , June 16, 2023 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as prec...